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BACKGROUND AND PURPOSE: Metabolic traits affect ischemic stroke (IS) risk, but the degree to which this varies across different 
ethnic ancestries is not known. Our aim was to apply Mendelian randomization to investigate the causal effects of type 2 
diabetes (T2D) liability and lipid traits on IS risk in African ancestry individuals, and to compare them to estimates obtained 
in European ancestry individuals.
METHODS: For African ancestry individuals, genetic proxies for T2D liability and circulating lipids were obtained from a meta-
analysis of the African Partnership for Chronic Disease Research study, the UK Biobank, and the Million Veteran Program 
(total N=77 061). Genetic association estimates for IS risk were obtained from the Consortium of Minority Population 
Genome-Wide Association Studies of Stroke (3734 cases and 18 317 controls). For European ancestry individuals, genetic 
proxies for the same metabolic traits were obtained from Million Veteran Program (lipids N=297 626, T2D N=148 726 
cases, and 965 732 controls), and genetic association estimates for IS risk were obtained from the MEGASTROKE study 
(34 217 cases and 406 111 controls). Random-effects inverse-variance weighted Mendelian randomization was used as the 
main method, complemented with sensitivity analyses more robust to pleiotropy.
RESULTS: Higher genetically proxied T2D liability, LDL-C (low-density lipoprotein cholesterol), total cholesterol and lower 
genetically proxied HDL-C (high-density lipoprotein cholesterol) were associated with increased risk of IS in African ancestry 
individuals (odds ratio per doubling the odds of T2D liability [95% CI], 1.09 [1.07–1.11]; per standard-deviation increase 
in LDL-C, 1.12 [1.04–1.21]; total cholesterol: 1.23 [1.06–1.43]; HDL-C, 0.93 [0.89–0.99]). There was no evidence for 
differences in these estimates when performing analyses in European ancestry individuals.
CONCLUSIONS: Our analyses support a causal effect of T2D liability and lipid traits on IS risk in African ancestry individuals, 
with Mendelian randomization estimates similar to those obtained in European ancestry individuals.
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affecting affluent regions, Africa now reports the highest 
incidence of stroke and the highest case fatality in the 
world.3 There is thus a growing need to understand the 
risk factors for stroke in African ancestry individuals.
Large multinational observational studies have 
established metabolic traits, such as dyslipidemia 
and type 2 diabetes (T2D), as risk factors for stroke.4 
However, it is not clear how the effects of these risk 
factors vary between individuals of different genetic 
ancestries. Ethnic variation in stroke risk factors has 
previously been explored in observational studies, but 
these are liable to confounding and reverse causation, 
limiting the ability to make causal inferences.5
To address these issues, Mendelian randomization 
(MR) employs genetic variants as proxies for an expo-
sure to study its effect on an outcome.6 MR is analogous 
to a randomized controlled trial with individuals being 
randomly assigned genetic variants at conception, mini-
mizing confounding and reverse causality. MR has been 
widely used to examine risk factors for stroke in Euro-
pean populations.7–9 However, similar studies in other 
ethnic groups have not been undertaken, largely due to 
paucity of genetic data on individuals of non-European 
populations. The publication of the COMPASS (Consor-
tium of Minority Population Genome-Wide Association 
Studies of Stroke)10 provides an opportunity to conduct 
MR studies in people of African ancestry.
Here, we used MR to investigate the causal effect of 
lipid traits and T2D liability on ischemic stroke (IS) risk in 
African ancestry populations and compared estimates to 
those obtained in individuals of European ancestry.
METHODS
Ethical Approval, Data Availability, and 
Reporting
We used summary data from published studies that obtained 
relevant ethical approval and participant consent. These data 
are available on request to the original studies. The analysis 
codes are available on request to the corresponding author, 
and all results are presented in the main article or its Data 
Supplement.
Genetic Association Estimates
We used 2-sample MR to investigate the associations of geneti-
cally proxied levels of five metabolic traits with IS risk: T2D liability, 
HDL-C (high-density lipoprotein cholesterol), LDL-C (low-density 
lipoprotein cholesterol), total cholesterol, and triglycerides. Genetic 
association estimates were obtained from publicly available sum-
mary statistics of genome-wide association studies (GWAS) 
detailed in Methods in the Data Supplement. Briefly, genetic 
associations for metabolic traits in African ancestry individuals 
were obtained from a meta-analysis of the African Partnership 
for Chronic Disease Research, self-reported Black participants in 
the UK Biobank, and African ancestry individuals in the Million 
Veteran Program, with a total of ≈77 000 participants. The genetic 
associations with the risk of IS were obtained from COMPASS, 
a GWAS meta-analysis of 3734 cases and 18 317 controls of 
African ancestry from 13 cohorts.10
For European ancestry individuals, genetic associations for 
the metabolic traits were obtained from the Million Veteran 
Program (T2D liability, 148 726 cases, 965 732 controls; lipids 
N=297 626) via database of Genotypes and Phenotypes.11,12 
The genetic associations with the risk of IS were obtained 
from the MEGASTROKE consortium (34 217 cases, 406 111 
controls, Methods in the Data Supplement).13 All genetic asso-
ciations for both ancestries were adjusted for age, sex, and 
population stratification.
Mendelian Randomization Analysis
For each exposure, we identified ancestry-specific instrumental 
variables for MR, based on GWAS on the exposure in the rel-
evant ethnic group: variants that associated with the exposure 
at P<5×10−8 and were available in the outcome dataset were 
clumped at r2<0.01 within ±500 kb, using the corresponding 
reference ancestry in 1000 Genomes Project. The remaining 
variants were used as instrumental variables for MR.
To measure instrument strength, we calculated the variance 
explained and F statistics for the individual variants. To evaluate 
statistical power, we calculated the minimum detectable odds 
ratio (OR) for each exposure at power=0.8, given the expo-
sure GWAS sample size, total variance explained by the genetic 
instruments (calculated as the sum of the variances explained 
by each individual instrument), and type I error rate=0.05.14
The main analyses estimating the association of genetically 
proxied levels of each exposure with risk of IS were performed 
using the random-effects inverse-variance weighted method.15 We 
examined the differences in the MR estimates between popula-
tions of European and African ancestries using the propagation 
of error method. Further sensitivity analyses—namely MR-Egger, 
weighted median, weighted mode, and contamination mixture 
method—were conducted to assess the robustness of the results to 
violations in instrumental variable assumptions (Methods in the Data 
Supplement).15 MR effect estimates are expressed as ORs per SD 
increase in genetically predicted levels of the exposure for continu-
ous traits, and per doubling the odds (log-OR per unit change in 
exposure log-odds multiplied by loge[2]) in the exposure for T2D.
RESULTS
The demographics for African ancestry individuals in UK 
Biobank are given in Table 1, and the demographics for 
Nonstandard Abbreviations and Acronyms
COMPASS  Consortium of Minority Population 
Genome-Wide Association Studies of 
Stroke
HDL-C high-density lipoprotein cholesterol
IS ischemic stroke
LDL-C low-density lipoprotein cholesterol
MR Mendelian randomization
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other considered populations can be found in their original 
publications.10–13,16 Table 2 provides minimum detectable 
ORs for MR analyses, and the association estimates for the 
variants used as instrumental variables and their individual 
F statistics are given in Table I in the Data Supplement.
In the MR analysis of African ancestry populations, 
higher genetically proxied T2D liability, LDL-C, and total 
cholesterol and lower genetically proxied HDL-C were 
associated with increased risk of IS (Figure; Table II in 
the Data Supplement). The MR estimate for triglycerides 
was similar in magnitude to the estimates for total cho-
lesterol, LDL-C, and inversely to HDL-C, however with 
95% CI for OR overlapping the null.
In European ancestry individuals, higher genetically 
proxied T2D liability, LDL-C, and lower genetically prox-
ied HDL-C were associated with increased risk of IS 
(Figure; Table II in the Data Supplement). The effect esti-
mate for genetically proxied total cholesterol was similar 
in the absolute value to other traits, however, with 95% 
CI for the OR marginally overlapping the null.
The comparison of MR estimates between European 
and African ancestry populations showed no strong 
evidence for differences in the MR estimates. The point 
estimates were marginally larger in African ancestry indi-
viduals for all traits (Table III in the Data Supplement). 
The associations between genetically proxied metabolic 
traits with the risk of IS were mostly consistent in the 
sensitivity analysis, apart from the estimates for HDL-C 
and triglycerides in European ancestry populations which 
were shrunk towards the null in the sensitivity analyses, 
implying some degree of horizontal pleiotropy (Table II 
and Figures I through VI in the Data Supplement).
DISCUSSION
This MR study found evidence for causal effects of lipid 
traits and T2D liability on IS risk for African ancestry indi-
viduals. When compared with the estimates obtained in 
European ancestry individuals, there was no evidence for 
marked differences in the effects.
These findings are of direct clinical relevance, as 
they support that optimization of these risk factors will 
be of benefit in reducing IS for all individuals, irrespec-
tive of ethnic background. However, although the effect 
of dyslipidemia and T2D on IS risk may be similar, it is 
also important to appreciate that the prevalence of these 
metabolic traits does vary considerably between differ-
ent ethnic groups,17 resulting in marked differences in 
the proportion of stroke that can be attributed to these 
risk factors.18
By leveraging large-scale genetic association data 
from African and European populations, we were able to 
investigate the comparative effects of T2D liability and 
lipid traits on stroke risk in these ethnic groups. The use 
of genetically proxied metabolic traits in MR approach 
offers robustness against environmental confound-
ing and reverse causation that can hinder causal infer-
ence in observational studies. The findings were mostly 





Age at recruitment in years 51.6 (46.3–58.9)
Female sex 59.0%
Type 2 diabetes 9.0%
Body mass index in kg/m2 28.8 (25.9–32.4)
Low-density lipoprotein cholesterol in mmol/L 3.3 (2.7–3.8)
High-density lipoprotein cholesterol in mmol/L 1.4 (1.2–1.7)
Triglycerides in mmol/L 1.0 (0.7–1.4)
Total cholesterol in mmol/L 5.2 (4.5–5.9)
Table 2. Exposure Summary Data and Statistical Power Calculations





African Type 2 diabetes 24 646 cases, 
31 446 controls
22 NA† NA†
High-density lipoprotein cholesterol 77 060 41 9.9 0.85
Low-density lipoprotein cholesterol 77 060 71 21.4 1.11
Total cholesterol 77 061 70 16.2 1.13
Triglycerides 77 061 27 7.3 1.20
European Type 2 diabetes 148 726 cases, 
965 732 controls
557 NA† NA†
High-density lipoprotein cholesterol 215 551 225 12.4 0.96
Low-density lipoprotein cholesterol 215 551 145 10.4 1.05
Total cholesterol 215 551 161 8.5 1.06
Triglycerides 215 551 200 11.9 1.05
The sources for the summary data are detailed in the Data Supplement. NA indicates not applicable.
*Minimum detectable odds ratio per 1 SD change in the exposure, at 80% power and type I error rate=0.05.
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consistent in sensitivity analyses more robust to the 
inclusion of pleiotropic variants, suggesting that this is 
unlikely to be a major source of bias.
The limitations of this work should be acknowledged. 
The statistical power may have been insufficient to identify 
small differences in the MR estimates between European 
and African ancestry populations. The binary categoriza-
tion of individuals as either of European or African ances-
try is an over-simplification and will not capture the wider 
genetic diversity of individuals within each group. Further-
more, there may also be a population effect that impacts 
the genetic associations for individuals of the same 
ancestry when considered in different contexts.19 Genetic 
association estimates were pooled from studies of hetero-
geneous populations with varying demographics. Despite 
the adjustments for age, sex, and population stratification, 
population heterogeneity may introduce bias to the MR 
estimates. Summary statistics for the Million Veteran Pro-
gram data were publicly available via database of Geno-
types and Phenotypes only for variants with P<10-4, and 
therefore, we were not able to conduct multivariable MR 
to investigate the mutually adjusted, direct effect of each 
considered cardiometabolic trait. Similarly, nor could we 
perform bidirectional MR to explore for reverse causality. 
We could not expand our analyses to other cardiometabolic 
traits, such as blood pressure or obesity, as sufficiently 
large GWAS summary statistics on these traits in African 
ancestry populations were not available to us. Finally, we 
were not able to examine the associations across differ-
ent stroke subtypes, as subtype-specific GWAS summary 
statistics were not available in COMPASS.
In conclusion, our results are consistent with T2D 
liability and lipid traits having a similar effect on IS risk in 
both African and European ancestry populations. Optimi-
zation of these risk factors will be of benefit for reducing 
the population burden of IS.
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